PMID: 9545996Apr 18, 1998Paper

Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients

The American Journal of Psychiatry
C TrichardJ L Martinot

Abstract

This study examined the binding to cortical serotonin 5-HT2A receptors of conventional doses of the typical neuroleptic chlorpromazine in comparison with clozapine, the prototype atypical antipsychotic, and amisulpride, a specific dopamine D2-D3 blocker. Seventeen schizophrenic patients treated with chlorpromazine (75-700 mg/day), four treated with clozapine (200-600 mg/day), and five treated with amisulpride (200-1200 mg/day) were studied. Cortical 5-HT2A binding was estimated by reference to the values for 14 antipsychotic-free schizophrenic subjects with the use of positron emission tomography and [18F]setoperone, a high-affinity radioligand for cortical 5-HT2A receptors. A dose-dependent decrease in the number of available cortical binding sites for [18F] setoperone was demonstrated in the chlorpromazine group; for the highest dose, there was a virtual lack of sites available for binding. A very low percentage of available binding sites was also observed in the clozapine-treated patients at all doses. This suggests a high level of 5-HT2A blockade with both clozapine and high doses of chlorpromazine. No significant binding of amisulpride to 5-HT2A receptors was detected. A high level of 5-HT2A receptor blockade does not appe...Continue Reading

Citations

Jun 22, 2002·The Cochrane Database of Systematic Reviews·N E MotaB G Soares
Sep 11, 2004·Journal of Psychopharmacology·Gavin P Reynolds
Oct 10, 2007·Harvard Review of Psychiatry·W Gordon Frankle
Aug 10, 2011·Biopharmaceutics & Drug Disposition·Jiang Ping LuoJim Fang
Mar 16, 2004·CNS Drugs·Jeffrey A Lieberman
Jun 16, 2011·Medicinal Research Reviews·Louise M PatersonGitte M Knudsen
Apr 16, 2013·Psychopharmacology·Roberto VivianiBirgit Abler
Dec 21, 2000·Current Psychiatry Reports·G D Pearlson
Jul 17, 2001·Nuclear Medicine Communications·L S Pilowsky
Feb 10, 2006·Expert Review of Neurotherapeutics·James M Stone, Lyn S Pilowsky
Nov 12, 2010·The Cochrane Database of Systematic Reviews·Claudia Asenjo LobosStefan Leucht
Nov 29, 2013·Journal of Labelled Compounds & Radiopharmaceuticals·Luc Zimmer, Didier Le Bars
Aug 27, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Robert M KesslerHerbert Y Meltzer
Mar 16, 2001·Expert Opinion on Pharmacotherapy·G P Reynolds
Jan 2, 2003·Annals of Nuclear Medicine·W Gordon Frankle, Marc Laruelle
Jul 20, 2006·Expert Opinion on Therapeutic Targets·Philip Seeman
Nov 4, 2004·CNS Drugs·Kate McKeage, Greg L Plosker
Jan 23, 2009·The Cochrane Database of Systematic Reviews·Adib EssaliJohn Rathbone
Sep 13, 2014·Current Behavioral Neuroscience Reports·Alexandra D ForrestSteven J Siegel
Sep 12, 2000·Psychiatry Research·P GovitrapongA Srikiatkhachorn
Mar 20, 2001·Comparative Biochemistry and Physiology. Toxicology & Pharmacology : CBP·A Berlind
Mar 20, 2010·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Neva H PatelAdil Al-Nahhas
Apr 25, 2013·Chemical Research in Toxicology·Nisha S SipesThomas B Knudsen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here